✦ LIBER ✦

Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma

✍ Scribed by Oki, Yasuhiro; Westin, Jason R.; Vega, Francisco; Chuang, Hubert; Fowler, Nathan; Neelapu, Sattva; Hagemeister, Fredrick B.; McLaughlin, Peter; Kwak, Larry W.; Romaguera, Jorge E.; Fanale, Michelle; Younes, Anas; Rodriguez, Maria Alma; Orlowski, Robert Z.; Wang, Michael; Ouzounian, Souzanne T.; Samaniego, Felipe; Fayad, Luis

Book ID: 121289875
Publisher: John Wiley and Sons
Year: 2013
Tongue: English
Weight: 371 KB
Volume: 163
Category: Article
ISSN: 0007-1048
DOI: 10.1111/bjh.12585

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Expression of eukaryotic initiation fact

Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine

✍ Kedar V. Inamdar; Jorge E. Romaguera; Elias Drakos; Ronald J. Knoblock; Mar Garc 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 389 KB 👁 1 views

Rituximab, cyclophosphamide-fractionated

Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma

✍ Mato, Anthony; Feldman, Tatyana; Zielonka, Tania; Singavi, Arun; Gadaletta, Gabr 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 321 KB

Rituximab plus HyperCVAD alternating wit

Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi

✍ Francesco Merli; Stefano Luminari; Fiorella Ilariucci; Mario Petrini; Carlo Visc 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB

Treatment of primary mediastinal large B

Treatment of primary mediastinal large B cell lymphoma with an alternating chemotherapy regimen based on high-dose methotrexate

✍ T. Fietz; W. U. Knauf; M. Hänel; A. Franke; M. Freund; E. Thiel; for the East Ge 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 177 KB

Low absolute lymphocyte count and additi

Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma

✍ Yu-Chung Huang; Chia-Jen Liu; Chun-Yu Liu; Jih-Tung Pai; Ying-Chung Hong; Hao-We 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 155 KB

Phase II study of a salvage regimen usin

Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma

✍ Yasuhiro Oki; Michinori Ogura; Harumi Kato; Ako Kikuchi; Hirofumi Taji; Yoshitoy 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB